Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the ...

Q4 2024 Earnings Call Transcript March 6, 2025 Xeris Biopharma Holdings, Inc. beats earnings expectations. Reported EPS is ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The FDA has filed the NDA submission for relacorilant to treat patients with Cushing syndrome (hypercortisolism).

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Supplements to reduce cortisol have been rising in popularity. They claim to lower stress levels. Are they legit?

Increased IV fluid manufacturing a welcome development, and news from the PBS. We welcomed the announcement this week of a shared $40 million ...

Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.

Hallmark symptoms of Cushing disease, including abdominal striae and facial rounding, were more common among younger patients than older patients.

Emphasising the urgent need to tackle rising obesity rates in India, the Prime Minister has called on nominated leaders to promote healthier lifestyles and comb ...

"Relacorilant’s combination of efficacy and safety gives it the potential to become the new standard of care for patients ...